title: Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy.
abstract: We reported a case of Hepatitis B virus-related membranous nephropathy (HBV-MN) with improvement under an ongoing 4.5-year of entecavir monotherapy. A 37 years old man with a 5 years' history of chronic hepatitis B (CHB) who was taken to our department because of proteinuria and microscopic haematuria. A renal biopsy led to a diagnosis of HBV-MN with mesangioproliferative. Interferon-alpha 2b (IFN-α2b) was stopped after 24 weeks due to the increasement of HBV-DNA and sustained HBeAg positive. Therefore, we started using 0.5mg entecavir per day. After 2 months' treatment, HBV-DNA was not detected in the blood, and the ALT and AST decreased to normal degree. After 3 years of entecavir therapy, virological tests revealed HBeAg seroconversion. With no further intervention during the next one and a half years, there was improvement of proteinuria gradually. This suggested that entecavir monotherapy may induce and maintain complete remission of membranous nephropathy associated with hepatitis B.
authors.affiliation: Liver Disease Department, The Second Hospital of Nanjing, The Second Affiliated Hospital of South East University, 1-1 Zhongfu Road, Nanjing 210003, Jiangsu Province, China.
authors.forename: Yong-Feng
authors.initials: YF
authors.lastname: Yang
authors.forename: Qing-Fang
authors.initials: QF
authors.lastname: Xiong
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.forename: Yan-Dan
authors.initials: YD
authors.lastname: Zhong
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy* / Q000209:etiology; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000150:complications; D006801:Humans; D008297:Male; D012074:Remission Induction
chemical_list: D000998:Antiviral Agents; C413685:entecavir; D006147:Guanine